세계의 예방 의약품 시장 : 유통 채널별, 전문 분야별 예측(2025-2030년)

The Preventive Medicines Market was valued at USD 376.49 billion in 2023, expected to reach USD 407.58 billion in 2024, and is projected to grow at a CAGR of 8.74%, to USD 676.98 billion by 2030.

Preventive medicines encompass a broad range of pharmaceuticals, vaccines, supplements, and lifestyle interventions aimed at preventing diseases before they occur. The growing necessity for preventive healthcare is driven by rising chronic disease prevalence, increasing healthcare costs, and heightened awareness around health and wellness. Its application spans across infectious diseases, chronic disease management, cancer prevention, and maternal-child health, with end-use scope including hospitals, clinics, research institutes, and direct-to-consumer platforms. The market is propelled by key factors such as technological advancements in diagnostics, increased investment in healthcare infrastructure, and the growing implementation of telemedicine. Growth potential lies in expanding immunization programs, the proliferation of wearable tech for self-monitoring, and the integration of AI in personalized preventive strategies.

Latest opportunities in the market include developing targeted vaccines for emerging pathogens, nutraceuticals tailored to genetic profiles, and mobile health applications that offer real-time health data. Companies can capitalize on these by investing in research and expanding their digital health capabilities. However, challenges such as regulatory hurdles, high R&D costs, and vaccine hesitancy can impede growth. Furthermore, the accessibility and affordability of preventive medicines in low-income regions remain significant barriers. Despite these challenges, innovation areas ripe for exploration include bioinformatics for disease prediction, plant-based vaccines, and CRISPR technology applications for hereditary disease prevention.

Strategically, businesses should focus on collaborations with tech firms to enhance precision medicine initiatives, engage in public-private partnerships to improve reach in underserved markets, and continuously invest in research to stay at the forefront of scientific breakthroughs. The nature of the market is dynamic and competitive, with emphasis shifting towards preventive measures that not only reduce incidence rates but also promote holistic health management. Companies that successfully navigate these complex factors, leveraging emerging technologies and fostering cross-industry collaborations, will likely secure sustainable growth in this evolving sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Preventive Medicines Market

The Preventive Medicines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prices of medicines, medical devices, medical treatments, and surgical procedures
  • Increasing interest of pharma companies in manufacturing of preventive medicine
  • Initiatives and events to spread education about the preventive medicines
• Market Restraints
  • Loosely defined regional confirmations referring to preventive drug
• Market Opportunities
  • Collaborative market ecosystem
  • Technology advancement to support prescription of tailor made solutions
• Market Challenges
  • Absence of proven evidences or studies citing preventive medicine

Porter's Five Forces: A Strategic Tool for Navigating the Preventive Medicines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Preventive Medicines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Preventive Medicines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Preventive Medicines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Preventive Medicines Market

A detailed market share analysis in the Preventive Medicines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Preventive Medicines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Preventive Medicines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Preventive Medicines Market

A strategic analysis of the Preventive Medicines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Preventive Medicines Market, highlighting leading vendors and their innovative profiles. These include Aetna Inc., Affymetrix, Inc, Cancer Prevention Pharmaceuticals, Inc, Dilon Technologies, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, McKesson Corporation, Medtronic PLC, Merck & Co. Inc., Myriad Genetics, Inc., Myriad Women's Health, Inc., Novo Nordisk A\S, Omada Health, Inc., Omnicell, Inc., and Pfizer, Inc..

Market Segmentation & Coverage

This research report categorizes the Preventive Medicines Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Distribution Channels, market is studied across Diagnostic Centers and Hospitals.
• Based on Specialty Areas, market is studied across Aerospace Medicine, General Preventive Medicine, Occupational Medicine, and Public Health.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prices of medicines, medical devices, medical treatments, and surgical procedures
    • 5.1.1.2. Increasing interest of pharma companies in manufacturing of preventive medicine
    • 5.1.1.3. Initiatives and events to spread education about the preventive medicines
  • 5.1.2. Restraints
    • 5.1.2.1. Loosely defined regional confirmations referring to preventive drug
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborative market ecosystem
    • 5.1.3.2. Technology advancement to support prescription of tailor made solutions
  • 5.1.4. Challenges
    • 5.1.4.1. Absence of proven evidences or studies citing preventive medicine
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Preventive Medicines Market, by Distribution Channels

• 6.1. Introduction
• 6.2. Diagnostic Centers
• 6.3. Hospitals

7. Preventive Medicines Market, by Specialty Areas

• 7.1. Introduction
• 7.2. Aerospace Medicine
• 7.3. General Preventive Medicine
• 7.4. Occupational Medicine
• 7.5. Public Health

8. Americas Preventive Medicines Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Preventive Medicines Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Preventive Medicines Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Aetna Inc.
• 2. Affymetrix, Inc
• 3. Cancer Prevention Pharmaceuticals, Inc
• 4. Dilon Technologies, Inc.
• 5. Eli Lilly and Company
• 6. GlaxoSmithKline PLC
• 7. McKesson Corporation
• 8. Medtronic PLC
• 9. Merck & Co. Inc.
• 10. Myriad Genetics, Inc.
• 11. Myriad Women's Health, Inc.
• 12. Novo Nordisk A\S
• 13. Omada Health, Inc.
• 14. Omnicell, Inc.
• 15. Pfizer, Inc.